Chalcogen Or Nitrogen Bonded Directly To The Hetero Ring Patents (Class 514/470)
-
Publication number: 20140315996Abstract: The use of one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms as antimicrobially active compound is described. The use is preferably in cosmetic, dermatological or pharmaceutical compositions, in crop protection formulations, in washing or cleaning compositions or in paints or coatings.Type: ApplicationFiled: July 31, 2012Publication date: October 23, 2014Applicant: CLARIANT INTERNATIONAL LTD.Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
-
Publication number: 20140309213Abstract: This invention relates to compounds of Formula I-VI having the following general structure: Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with —(CH2)n1— and —(CH2)n2—, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: ApplicationFiled: October 25, 2012Publication date: October 16, 2014Inventors: Shawn P. Walsh, Alexander Pasternak, Reynalda K. DeJesus, Haifeng Tang, Barbara Pio, Aurash Shahripour, Kevin M. Belyk, Harry R. Chobanian, Yan Guo, Jessica L. Frie, Zhi-Cai Shi, Helen Chen, Timothy A. Blizzard, Brian Cato
-
Patent number: 8853430Abstract: The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it.Type: GrantFiled: May 20, 2010Date of Patent: October 7, 2014Assignee: Hetero Research FoundationInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Rapolu Raji Reddy, Bandi Vamsi Krishna, Kesireddy Subash Chander Reddy
-
Publication number: 20140288027Abstract: (?)-(S)-3-(3?-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.Type: ApplicationFiled: September 26, 2012Publication date: September 25, 2014Inventors: Wei Wang, Yayao Zhou, Ya'nan Liu
-
Publication number: 20140288169Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.Type: ApplicationFiled: January 5, 2012Publication date: September 25, 2014Applicant: TARGACEPT, INC.Inventors: Srinivasa Rao Akireddy, Scott R. Breining, Matt S. Melvin, Srinivasa V. Murthy, Anatoly A. Mazurov, Balwinder Singh Bhatti, Jon-Paul Strachan, Ronald Joseph Heemstra, Todd Showalter, Yunde Xiao, Philip S. Hammond, Lan Miao, David Kombo, Daniel Yohannes, Jason Speake
-
Publication number: 20140271568Abstract: A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell.Type: ApplicationFiled: March 6, 2014Publication date: September 18, 2014Applicant: Hawking Biological Technology Co., LtdInventors: Shinn-Zong LIN, Horng-Jyh Harn, Tzyy-Wen Chiou, Kuo-Wei Hsueh, Mao-Hsuan Huang
-
Publication number: 20140274936Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: SYNTHONICS, INC.Inventors: Thomas Piccariello, John D. Price, Robert A. Oberlender, Michaela E. Mulhare, Mary C. Spencer, Scott B. Palmer
-
Patent number: 8835659Abstract: The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer, aging related diseases or processes, diabetes and neurodegenerative diseases.Type: GrantFiled: May 10, 2011Date of Patent: September 16, 2014Assignees: Ikerchem, S.L., Universidad del Pais VascoInventors: Fernando Pedro Cossio Mora, Leire Lidia Arias Echeverría, Yosu Ion Vara Zalazar, Eneko Aldaba Arévalo, Eider San Sebastián Larzabal, Aizpea Zubia Olascoaga
-
Publication number: 20140256782Abstract: Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic is visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.Type: ApplicationFiled: October 19, 2012Publication date: September 11, 2014Applicant: Bikam Pharmaceuticals, Inc.Inventors: David S. Garvey, Gregory J. Larosa, Jeremy R. Greenwood, Leah L. Frye, Tan Quach, Jamie B. Cote, Judd Berman
-
Publication number: 20140255426Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a Wnt pathway inhibitor optionally in combination with one or more anti-viral agents. In certain embodiments, the subject is diagnosed with a chronic viral infection such as human immunodeficiency virus (HIV).Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Applicants: EMORY UNIVERSITY, Children's Healthcare of Atlanta, Inc., The General Hospital CorporationInventors: Guido Silvestri, Ann M. Chahroudi, Mathias Lichterfeld, Maria Jose Buzon, Raymond F. Schinazi
-
Patent number: 8822530Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: GrantFiled: March 11, 2013Date of Patent: September 2, 2014Assignee: Allergan, Inc.Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
-
Publication number: 20140235528Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: ApplicationFiled: April 24, 2014Publication date: August 21, 2014Applicant: DUKE UNIVERSITYInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 8802724Abstract: The invention described herein pertains to processes and compounds useful in the preparation of bis-tetrahydrofurans. The invention described herein also pertains to compounds useful for treating HIV infections.Type: GrantFiled: November 30, 2011Date of Patent: August 12, 2014Assignee: Purdue Research FoundationInventors: Arun K. Ghosh, Cuthbert D Martyr
-
Publication number: 20140221474Abstract: A chemical peeling formulation and a formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling, comprising at least one keratolytic agent and dimethyl isosorbide. The composition may additionally comprise dimethyl sulphone.Type: ApplicationFiled: February 24, 2014Publication date: August 7, 2014Inventor: Gianfranco de Paoli Ambrosi
-
Publication number: 20140221468Abstract: Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired.Type: ApplicationFiled: December 9, 2011Publication date: August 7, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chan Young Park, Amir M. Sadaghiani, Ricardo Ei Dolmetsch
-
Publication number: 20140221431Abstract: Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof. The inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, immune system diseases, genetic diseases and nerve system diseases. The histone deacetylase inhibitor of benzamides is a compound of the following general chemical structural formula (I) or a salt thereof.Type: ApplicationFiled: June 26, 2012Publication date: August 7, 2014Applicants: Shanghai Institute of Pharmaceutical Industry, Sinopharm A-think Pharmaceutical Co., LtdInventors: Jianqi Li, Qingwei Zhang, Zhidan Jia, Jiajing Wang
-
Publication number: 20140221351Abstract: The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: April 8, 2014Publication date: August 7, 2014Applicant: ALLERGAN, INC.Inventors: HAIQING YUAN, RICHARD L. BEARD, XIAOXIA LIU, JOHN E. DONELLO, VEENA VISWANATH, MICHAEL E. GARST
-
Publication number: 20140213533Abstract: Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3? mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts.Type: ApplicationFiled: January 31, 2014Publication date: July 31, 2014Inventors: Manikkam Suthanthiran, Ruchuang Ding, Joseph E. Schwartz, Abraham Shaked
-
Publication number: 20140186278Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.Type: ApplicationFiled: September 19, 2013Publication date: July 3, 2014Inventor: Patrick Franke
-
Publication number: 20140187481Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: ApplicationFiled: July 3, 2013Publication date: July 3, 2014Inventors: Arthur Tudor Tucker, Nigel Benjamin
-
Patent number: 8765791Abstract: The present invention relates to methods for treating cancer by administering a therapeutically effective amount of compound of formula (I), such as selective NPY5R antagonist MK-0557 (trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H), 1?-cyclohexane]-4?-carboxamide), or a pharmaceutically acceptable salt thereof, to a subject in need thereof The methods can further comprise administering a chemotherapeutic agent to the subject in need thereof.Type: GrantFiled: March 10, 2009Date of Patent: July 1, 2014Assignee: University Health NetworkInventor: Guohua Pan
-
Patent number: 8759379Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: GrantFiled: December 19, 2008Date of Patent: June 24, 2014Assignee: Gilead Sciences, Inc.Inventors: Manoj C. Desai, Hon C. Hui, Hongtao Liu, Lianhong Xu
-
Publication number: 20140171499Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.Type: ApplicationFiled: February 19, 2014Publication date: June 19, 2014Applicant: Janssen R&D IrelandInventors: Hans Wim Pieter VERMEERSCH, Daniel Joseph Christiaan THONE, Luc Donne Marie-Louise JANSSENS, Piet Tom Bert Paul WIGERINCK
-
Publication number: 20140155350Abstract: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: SineVir Therapeutics LLCInventors: John Hilfinger, Gordon Amidon
-
Patent number: 8741334Abstract: In a plaster for external use for transdermal absorption in which an adhesive layer is laminated on a plastic backing, the adhesive layer contains a styrene-isoprene-styrene block copolymer (SIS), a tackifying resin and a softener which are essential ingredients, and further contains flurbiprofen blended as an active ingredient. The present plaster for external use is a flurbiprofen containing plaster for external use enabling long-term stable release of contained flurbiprofen, and having excellent stability and very high drug releasing property.Type: GrantFiled: February 28, 2005Date of Patent: June 3, 2014Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Masahiro Yamaji, Takaya Sugawara
-
Publication number: 20140147529Abstract: The present invention relates to a method for reducing the production of methane emanating from the digestive activities of a ruminant and/or for improving ruminant animal performance by using, as active compound at least one organic molecule substituted at any position with at least one nitrooxy group, or a salt thereof, which is administrated to the animal together with the feed. The invention also relates to the use of these compounds in feed and feed additives such as premix, concentrates and total mixed ration (TMR) or in the form of a bolus.Type: ApplicationFiled: December 20, 2011Publication date: May 29, 2014Applicant: DSM IP ASSETS B.V.Inventors: Stephane Duval, Maik Kindermann
-
Publication number: 20140148508Abstract: C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds and/or compositions for treating patients infected with HIV are also described.Type: ApplicationFiled: July 11, 2012Publication date: May 29, 2014Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, PURDUE RESEARCH FOUNDATIONInventors: Arun K. Ghosh, Hiroaki Mitsuya, Bruno D. Chapsal
-
Publication number: 20140142170Abstract: A composition and method for influencing energy metabolism and treating metabolic and other disorders is provided. A terpenoid lactone that is a selective activator of SIRT1 is generally in the form of a terpenoid dilactone having a 5-alkeny-loxy-furan-2- one group, such as strigolactone, GR 24, or another strigolactone analog, and is used as a therapeutic agent in a method for influencing energy metabolism and treating metabolic and other disorders. The terpenoid lactone may be administered as an individual agent or combined with a second compound such as a flavonoid, chalconoid, tannin, or nicotinamide inhibition antagonist.Type: ApplicationFiled: October 27, 2011Publication date: May 22, 2014Applicant: SIRTUIN VALLEY OYInventors: Markku Laakso, Nagendra Yaluri
-
Publication number: 20140142174Abstract: This invention relates to solid oral dosage forms of the HIV inhibitor darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof.Type: ApplicationFiled: July 6, 2012Publication date: May 22, 2014Inventors: Urbain Alfons C. Delaet, Philip Erna H. Heyns, Eugeen Maria Josef Jans
-
Patent number: 8728518Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.Type: GrantFiled: August 26, 2005Date of Patent: May 20, 2014Assignee: CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., LtdInventors: Zhentao Liu, Liying Yang, Hanyu Yang, Yuqing Gao, Dongmin Shen, Wenmin Guo, Xiaolong Feng, Jia Zheng
-
Publication number: 20140135373Abstract: Compound with formula (I), wherein R? and R? represent a hydrogen atom, a monovalent radical with formula (IIa), or a monovalent radical with formula (IIb), it being understood that at least one of the R? or R? radicals does not represent a hydrogen atom and that when the R? and R? radicals do not represent a hydrogen atom, R? and R? are identical; method for preparing and using in cosmetics and as a drug.Type: ApplicationFiled: May 24, 2012Publication date: May 15, 2014Applicant: SOCIETE D'EXPLOITATION DE PROUITS POUR LES INDUSTRIES CHMIQUES SEPPICInventors: Andre Benattar, Laetitia Cattuzzato, Sandy Dumont, Stephanie Garcel, Jerome Guilbot, Sebastien Kkerverdo, Herve Rolland
-
Publication number: 20140135321Abstract: Described herein are compounds, compositions, and methods for treating HIV and related diseases.Type: ApplicationFiled: January 16, 2014Publication date: May 15, 2014Inventor: Arun K. GHOSH
-
Publication number: 20140121246Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.Type: ApplicationFiled: October 15, 2013Publication date: May 1, 2014Applicant: Metabolex, Inc.Inventors: Dong Fang Shi, Jiangao Song, Christopher J. Rabbat, Jingyuan Ma, Aaron Novack, Imad Nashashibi, Xin Chen
-
Publication number: 20140113897Abstract: The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.Type: ApplicationFiled: May 22, 2012Publication date: April 24, 2014Applicant: THE WISTAR INSTITUTEInventors: Paul M. Lieberman, Troy Messick
-
Patent number: 8703814Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: GrantFiled: May 22, 2013Date of Patent: April 22, 2014Assignee: Korea Ocean Research and Development InstituteInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Patent number: 8697745Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: GrantFiled: May 22, 2013Date of Patent: April 15, 2014Assignee: Korea Ocean Research InstituteInventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
-
Publication number: 20140094514Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.Type: ApplicationFiled: May 22, 2013Publication date: April 3, 2014Applicant: Korea Ocean Research and Development InstituteInventors: Joung Han YIM, Il Chan KIM, Doc Kyu KIM, Se Jong HAN, Hyoung Seok LEE, Bhattarai HARI DATTA, Jung Eun KIM, Tai Kyoung KIM, Hyun Cheol OH, Dong-Gyu JO, Cheolsoon LEE, Keun-Sik KIM, Pyung Cheon LEE, Mi Ra PARK, Yu-Kyung PARK, Sung Jin KIM, Pil-Sung KANG, Heeyong PARK, Ha Ju PARK
-
Publication number: 20140094466Abstract: In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment compositions of the invention slow or inhibit F-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit, or reverse, or ameliorate the progression of a cancer or a metastasis or other uncontrolled or unregulated cell growth, and/or Alzheimer's disease.Type: ApplicationFiled: March 15, 2012Publication date: April 3, 2014Inventors: Jason H. Haga, Shu Chien, Matt Mui, Marshall J. Levesque, Phillip D. Pham
-
Patent number: 8686031Abstract: The present invention provides novel flavonoids extracted from an alcohol extract of dehulled adlay seeds. The present invention also provides a process for the preparation of the flavonoid and a method for treating inflammation in a subject, which method comprises administering to said subject an effective amount of the flavonoid and a pharmaceutically acceptable carrier or excipient.Type: GrantFiled: December 19, 2011Date of Patent: April 1, 2014Assignee: Joben Bio-Medical Co., Ltd.Inventors: Wenchang Chiang, Yun-Lian Lin, Cheng-Pei Chung, Hong-Jhang Chen
-
Publication number: 20140088161Abstract: The present invention relates to the field of reduction of methane emission in ruminants. Particularly, it relates to the use of a feed composition or a feed additive comprising at least one antibiotic and at least one organic molecule substituted at any position with at least one nitrooxy group for reducing the production of methane emanating from the digestive activities of ruminants, and/or to improve the ruminant performance.Type: ApplicationFiled: May 25, 2012Publication date: March 27, 2014Applicant: DSM IP ASSETS B.V.Inventors: Stephane Duval, Irmgard Immig, Maik Kindermann, Gilbert Weber
-
Patent number: 8680135Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.Type: GrantFiled: October 22, 2012Date of Patent: March 25, 2014Assignee: Bionomics LimitedInventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
-
Publication number: 20140080780Abstract: Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.Type: ApplicationFiled: May 21, 2012Publication date: March 20, 2014Inventor: Benjamin WOLOZIN
-
Patent number: 8673970Abstract: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.Type: GrantFiled: February 23, 2009Date of Patent: March 18, 2014Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, John W. Erickson
-
Publication number: 20140072536Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Applicant: Board of Regents of the Nevada System of Higher Education On Behalf of the University of NevadaInventors: Ryan Wuebbles, Dean Burkin
-
Patent number: 8664266Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.Type: GrantFiled: April 30, 2013Date of Patent: March 4, 2014Assignee: Fred Hutchinson Cancer Research CenterInventors: Valeri I. Vasioukhin, John R. Chevillet
-
Publication number: 20140057977Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.Type: ApplicationFiled: May 29, 2013Publication date: February 27, 2014Inventor: Michaela Gorath
-
Publication number: 20140056964Abstract: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.Type: ApplicationFiled: December 6, 2011Publication date: February 27, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Paul R. Hiebert, Darryl A. Knight, David J. Granville, Wendy A. Boivin, Dawn M. Cooper
-
Publication number: 20140057978Abstract: Provided herein are compounds for use in the treatment of central nervous system (CNS)-trauma related disorders like spinal cord injuries. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use for the treatment of (CNS)-trauma related disorders are also disclosed.Type: ApplicationFiled: March 9, 2012Publication date: February 27, 2014Applicant: ALGIAX PHARMACEUTICALS GMBHInventors: Guido Koopmans, Birgit Hasse
-
Publication number: 20140045765Abstract: A method for inhibiting the autophagy of motor neurons in a subject is provided. The method comprises administrating to the subject an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound and combinations thereof: wherein A is a C1-C5 alkyl optionally having one or more unsaturated bonds and optionally being substituted by one or more substituents selected from a group consisting of —OH, ?O and C1-C3 alkyl; X is H, —OH, Y is O or S and can optionally combine with A to form a five-membered ring; and R1 is H or a substituted or unsubstituted C1-C20 alkyl, wherein one or more —CH2— of the C1-C20 alkyl are optionally being replaced by —NH— or —O—.Type: ApplicationFiled: December 4, 2012Publication date: February 13, 2014Applicant: China Medical UniversityInventors: Shinn-Zong Lin, Horng-Jyh Harn, Tzyy-Wen Chiou, Kuo-Wei Hsueh
-
Publication number: 20140037547Abstract: The present invention relates to cGMP protein kinase (PKG) and regulatory domains and methods of use thereof. The structural determination of PKG domains is also described. cGMP independent PKG activators and uses thereof are also described.Type: ApplicationFiled: March 13, 2013Publication date: February 6, 2014Applicant: The University of Vermont and State Agricultural CollegeInventors: Wolfgang Dostmann, Brent W. Osborne, Thomas M. Moon